Tilray is engaged in supplying medical cannabis products to patients in various countries spanning five continents across the world. Co.'s medical brand, Tilray is designed to target the global medical market by providing a range of medical cannabis and cannabinoid-based products. Co.'s global portfolio of medical cannabis products includes the following form factor platforms: whole flower; ground flower; oil drops and capsules; purified oil drops and capsules; and clinical compounds. In addition, Co. also developed and launched brands for the adult-use market in Canada which are wholly owned by Co., such as CANACA, Yukon Rove and Dubon, The Batch/La Batch and Chowie Wowie. The TLRY stock yearly return is shown above.
The yearly return on the TLRY stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2019 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the TLRY annual return calculation with any dividends reinvested as applicable (on ex-dates).
|